ESTRO 2024 - Abstract Book

S924

Clinical - CNS

ESTRO 2024

Results:

We identified 545 patients with histological grade 2-3 gliomas. For patients >40 years, 46% of gliomas were IDH wildtype compared to just 10% in patients <40 years (P < .001). For all patients, age >40 years was associated with poorer PFS (2.7 vs. 7.5 years, P < .001, HR = 1.97 [95%CI 1.56-2.49]). Among patients with IDH-mutant tumors (n=409), age >40 years had no effect on PFS (8.2 vs. 7.9 years, P = .30, HR = 1.16 [95%CI 0.85-1.57]. Age also had no effect on PFS for patients with grade 2 IDH-mutant gliomas (9.1 vs. 9.3 years, P = .98, HR = 1.01 [95%CI 0.62-1.62]). Similar results for PFS were observed for patients IDH-mutant tumors in the TCGA (n=415) and GLASS (n=66) cohorts and for overall survival in the DFCI (n=122) cohort.

Conclusion:

Our analysis suggests that age is a surrogate for IDH-status but not an independent risk factor for progression in diffuse gliomas. If these findings are validated within the RTOG 9802, RTOG 0424, and EORTC 22033 trials, there may be sufficient evidence to remove age as an indication for chemoradiotherapy from clinical practice guidelines.

Keywords: glioma, IDH, age

References:

Kinslow, CJ, Mercurio A, Kumar P, et al. Association of MGMT Promoter Methylation with Survival in Low-Grade and Anaplastic Gliomas after Alkylating Chemotherapy. JAMA Oncology, 2023.

2566

Digital Poster

Automated Contouring, Planning, and Quality Assurance for VMAT Craniospinal Irradiation (VMAT-CSI)